Introduction
============

Historically, viral infections associated with abnormal cell growth have been reported and studied directly from tumours ([@ref-31]). Among others, several herpesviruses can lead to tumour formation in humans ([@ref-11]) and other vertebrates such as reptiles ([@ref-3]). The marine turtle disease fibropapillomatosis (FP), has been linked to infection by the Chelonid herpesvirus 5 (ChHV5) also commonly known as the Chelonid fibropapilloma-associated herpesvirus (CFPHV) ([@ref-12]). Despite, all attempts at culturing ChHV5 *in vitro* have been unsuccessful ([@ref-22]; [@ref-30]). Thus, confirmation of ChHV5 as the primary causal agent of FP tumours remains inconclusive as defined by the four Koch's postulates that establish relationships to identify the causative agent of a disease.

Several studies have used quantitative real time PCR (*q*PCR) methods to assay the levels of ChHV5 DNA in marine turtle tissues, in an attempt to shed further light into its potential relevance for FP. While most of such *q*PCR assays have exclusively targeted the skin tumours ([@ref-30]), conjunctival growths, and/or tumours from visceral organs ([@ref-4]) sampled from FP affected turtles, non-tumour skin tissue samples of infected animals have been used to demonstrate that ChHV5 is always found at higher level in FP tumours than in healthy tissue samples from affected animals ([@ref-24]). Although this has been interpreted as further evidence for ChHV5s role in FP, little attention has been given to the levels of ChHV5 in clinically healthy turtles, whether from feeding grounds shared with FP affected individuals or from species' populations in which FP has never been observed. Only a handful of research studies, exclusively focused on populations historically documented with individuals infected by the FP disease, have described the detection of herpes viral DNA from clinically healthy marine turtles ([@ref-16]).

In a recent series of studies we documented the presence of ChHV5 DNA sequences in a global sample set of five species of clinically healthy marine turtles, using sequenced PCR amplicons ([@ref-2]; [@ref-1]). In the same studies, we also investigated the possibility that these viral amplicons have been integrated in the turtle genome ([@ref-29]), and finding no evidence for this hypothesis, we confirmed the presence of ChHV5 DNA in healthy individuals. We did emphasise the presence of Glycoprotein *B* (g*B*) amplicons, a well-characterized protein involved in the viral cell entry, in clinically healthy turtles. This immediately begs questions as: (i) if ChHV5 is the etiological agent for FP, how can it be found in asymptomatic animals; and (ii) how do levels of ChHV5 in healthy animals compare to those originating from FP samples? To investigate this, we aimed to determine the relative concentration of ChHV5 Glycoprotein *B* (g*B*) to host nuclear DNA ratio in a sub-sample set from a recently published work ([@ref-2]) including FP positive and negative sea turtle tissue samples using a real-time polymerase chain reaction (*q*PCR) assay in order to provide further evidence of the ChHV5 latency distinctive feature.

Materials and Methods
=====================

Data collection
---------------

Our dataset consisted of: ten paired tumour and non-tumour tissue samples from cases of FP in green turtles (*Chelonia mydas*) obtained from warmer climates in three geographically distant populations; Hawaii in the Pacific, Turks & Caicos in the Caribbean, and Príncipe Island off the Western coast of Africa. Five additional FP tumour and one non-tumour samples from the same populations were also included. Moreover, 16 DNA samples from four clinically healthy turtle species from other oceanic areas and several distant turtle populations were analysed: six hawksbills (*Eretmochelys imbricata*) from Principe Island and Qaru Island Kuwait; three loggerheads (*Caretta caretta*), two from Cyprus and one rehabilitated in a Danish aquarium; two leatherbacks (*Dermochelys coriacea*) from Ghana; and five DNA extracts from two green turtle individuals, one from Tortuguero (Costa Rica) and one from Denmark (four DNA extracts). This last green turtle that originated from the same previously mentioned Danish aquarium, was the only turtle that was sampled post mortem, and as such multiple skin and internal organs samples were available for analysis. In this study, a clinically healthy turtle is defined as an animal that exhibited no visual FP tumours or any other clinical signs of illness.

Combined dermis and epidermis cross sections of the surface tissue samples (5--10 mm depth) were taken from the trailing edge of the front flippers and neck of the turtles using a scalpel. A standard protocol for tissue collection was generally followed in this study ([@ref-8]).

DNA was extracted from approximately 25 mg tissue samples using the DNeasy Tissue Kit (Qiagen, Valencia, CA, USA) following the manufacturer's instructions. Samples were incubated with agitation for 24 h at 56 °C. The samples were then centrifuged for 5 min at 10,000 g to pellet any remaining cellular material and the supernatant was transferred into a 2 ml DNeasy Mini spin column placed in a 2 ml collection tube and centrifuged for 1 min at 8,000 g. Finally purified genomic DNA was eluted in 50 µl of Qiagen EB buffer. Extraction blanks were included to monitor for contamination. All DNA extracts and blanks were assessed and tested by singleplex PCR ([@ref-2]) in order to check for amplification of the correct target size, and thus to ensure presence of ChHV5 and turtle DNA for quality control purposes.

All tissue skin samples were collected in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (Eighth Edition, 2011); and exported under relevant CITES permits (host institute permit DK03). Collection of samples from Hawaii was approved by permit No: SWP I2010-03 issued by the IACUC at National Oceanic and Atmospheric Administration (NOAA). All FP tumour samples were originated from turtles that stranded with terminal FP and tissues were collected during post-mortem examination.

Approvals for the work in Turks and Caicos Islands were obtained through the Department of Environment and Maritime Affairs (DEMA). Nesting beaches (some within protected areas) were accessed with permission from landowners and DEMA. All harvested turtles were sampled as part of the legal turtle fishery with permission from fishermen, processing plants and DEMA. Samples were exported using multiple CITES permits and UK Animal Health and Veterinary Laboratories Agency permits. Permits and sample collection from Principe Island were carried out in cooperation between Zoomarine and the Faculty of Science and Technology at University of Algarve, Portugal.

Most healthy tissue samples were collected from necrotic stranded turtles. Samples from Kuwait and Costa Rica were originated from live animals following protocols approved by Kuwaiti Coast Guard and Universidad de Costa Rica (UCR) in cooperation with the Costa Rican Ministry of Environment and Energy (MINAE), respectively. Tissue sample collection followed different protocols from our various collaborators, however the majority were obtained from either skin of front flipper or neck of the turtles following the standard procedure for collection of turtle tissue samples ([@ref-8]).

Real-time *q*PCR assay
----------------------

The DNA quantification assay was developed and tested on a Roche LightCycler 480 Real-time PCR System using SYBR Green chemistry. Although SYBR Green chemistry is less target specific than motif-specific probes such as TaqMan, we selected the former due to its greater flexibility ([@ref-28]), thus increasing our chances of amplifying DNA sequences of targets that could contain unknown variation (which given the paucity of comparative ChHV5 sequence available, is a distinct possibility).

Two sets of oligonucleotide primers designed to target highly conserved markers in ChHV5 Glycoprotein *B* (g*B*) gene UL27 and endogenous turtle (*nu*DNA) nuclear clone CM12 DNA were used for the *q*PCR assay (see [Table 1](#table-1){ref-type="table"}).
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###### List of primers used in this study.

List of primer sets designed and tested for ChHV5 and endogenous turtle (*nu*DNA) DNA.
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  Primer set                                   Targeted gene                                 Primer sequence (5′to '3)        Length (bases)
  -------------------------------------------- --------------------------------------------- -------------------------------- ----------------
  **UL27**[^a^](#table-1fn1){ref-type="fn"}    **Viral ChHV5 (Glycoprotein B gene UL27)**    F: CTCCGGATGGTCGCTGGC            143
                                                                                             R: CTAGATACATACTGGCCRTGCTCGTC    
  **nuDNA**[^a^](#table-1fn1){ref-type="fn"}   **Turtle genomic (nuclear DNA clone CM12)**   F: ACATTGTGCTAAAAAGCAATTGTGCCT   127
                                                                                             R: ACACCAGTCATGTGGAGTGGCA        

**Notes.**

Final primer sets used in the *q*PCR assay performed accordingly to the highest quality control checks and provided the most consistent standards curves.

These two set of primers provided the most consistent standards curves (empirically 3.32 cycles in a perfectly efficient reaction by checking if each 10% dilution crosses the fluorescence threshold after the higher concentration ([@ref-28]). We used g*B* primer set as it has been proven more sensitive than other oligonucleotide primers available ([@ref-2]). Each 25 µL *qPCR* reaction contained 1 U AmpliTaq Gold polymerase (Applied Biosystems, Foster City, CA, USA), 1X AmpliTaq Gold buffer, 2.5 mM MgCl~2~, 0.2 mM dNTPs, 0.4 mM primers, 1 µL 1X SYBR Green/ROX mix (Invitrogen, Carlsbad, CA, USA), and 1 µL of template DNA. Cycling conditions for the *q*PCR assay were as follows: 95.0 °C for 10 min enzyme activation, 50 cycles of 95.0 °C for 30 s, 60.0 °C for 1 min, and 72.0 °C for 1 min, followed by a melting (disassociation) curve. In order to monitor amplification dynamics and identify amplification inhibition and other experimental errors that may not be observed when only testing undiluted samples, each sample was tested in two dilution series, with a template DNA at concentrations of: 100%, 10%, and 1%; and 100%, 50% and 25%, respectively. A negative blank control was also included for all *q*PCR runs. Moreover, a series of dilutions of a standard tumour sample, obtained from our collaborators in Hawaii ([@ref-30]) was included for every *q*PCR run, which served as positive quality control and optimized the obtained cycle threshold (C~*t*~) values ([@ref-28]).

In order to estimate the absolute concentration of viral g*B* and endogenous turtle nuDNA markers per µL of DNA extract in each individual specimen, a comparison was made against a well-characterized sample, *Cm-TCFP-14* (standard sample). PCR amplicons of viral g*B* and nuDNA markers were measured on a Qubit 2.0 fluorometer (Life Technologies, Carlsbad, CA) and after accounting for the specific mass of each amplicon, diluted to make standard series from 10^8^ to 10^1^ markers per µL. These standards were then used in the *q*PCR analyses as calibration for the viral g*B* and nuDNA concentrations in the different extracts. In order to assess nucleic acids loads relationship between viral g*B* and turtle nuclear DNA, the ratio of viral g*B* to turtle nuclear DNA was calculated. To test for significant differences in media levels of DNA concentrations, we used the non-parametric method Mann--Whitney--Wilcoxon test (W-t), and for the means, parametric method *t*-test (t-t) were applied to evaluate ratios dataset using [r]{.smallcaps} v 3.1.0 ([@ref-26]). Although the starting tissue mass was only estimated to be similar between all samples, the estimated nuDNA levels were overall consistent ([Fig. 2A](#fig-2){ref-type="fig"}), with the exception of exceedingly high values of clinically healthy tissue from one of the green turtles taken post mortem from an individual held in a Danish aquarium. The tissue samples were directly frozen in the absence of preservative (−18 °C) and DNA was extracted only 12 h later, which may explain the particularly high quality. However, no significant difference was seen in the nuDNA concentration between the three groups (W-t, *p* = 0.53; and t-t, *p* = 0.69). When adjusting for estimated original tissue mass and DNA extraction elute volume (50 µL DNA extract to 25 µL PCR reaction product), these figures represent 9.9^*E*+04^ (FP tumour), 3.7^*E*+01^ (FP non-tumour) and 1.0^*E*+04^ (clinically healthy animal tissue) copies per mg tissue analysed. Detailed list of samples analysed in this *q*PCR assay listed by species and population; and value results obtained are listed in [Table 2](#table-2){ref-type="table"} and [Data S1](#supp-1){ref-type="supplementary-material"} ---Copy number loads of g*B* and nuDNA per turtle sample grouped by health status tissue.
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###### Detailed list of samples analysed in the *q*PCR assay listed by type of tissue, and providing C~*t*~ value results from the DNA quantification.

List of DNA extract samples analysed for quantification of Glycoprotein *B* (g*B*) to endogenous nuclear host (nuDNA), including; sample ID, species, type of tissue, population origin, cycle threshold values per marker, estimated copy number and calculated ration g*B*/nuDNA.
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  Health status        Sample ID                              Species                                      Population (sample origin)      C~*t*~ turtle nuDNA   C~*t*~ ChHV5 g*B*   nuDNA copy number   ChHV5 g*B* copy number   Ratio copy number g*B*/nuDNA
  -------------------- -------------------------------------- -------------------------------------------- ------------------------------- --------------------- ------------------- ------------------- ------------------------ ------------------------------
  FP tumour            Cm-HaFP-11neck                         *Chelonia mydas* (green)                     Hawaii, USA, Northern Pacific   23.06                 22.70               2,630               414                      **0.16**
  Cm-HaFP-14RHF        *Chelonia mydas* (green)               Hawaii, USA, Northern Pacific                20.93                           18.25                 23,400              155,000             **6.62**                 
  Cm-HaFP-2LHF         *Chelonia mydas* (green)               Hawaii, USA, Northern Pacific                24.12                           17.14                 2,130               118,778             **55.76**                
  Cm-HaFP-3LHF         *Chelonia mydas* (green)               Hawaii, USA, Northern Pacific                24.12                           20.93                 925                 10,450              **11.29**                
  Cm-HaFP-4neck        *Chelonia mydas* (green)               Hawaii, USA, Northern Pacific                23.89                           20.98                 1,073               10,120              **9.44**                 
  Cm-HaFP-8maxilla     *Chelonia mydas* (green)               Hawaii, USA, Northern Pacific                20.45                           16.81                 22,420              214,279             **9.56**                 
  Cm-PiFP-04           *Chelonia mydas* (green)               Principe Island, Western Africa              16.90                           18.51                 94,911              49,335              **0.52**                 
  Cm-PiFP-20           *Chelonia mydas* (green)               Principe Island, Western Africa              25.95                           20.71                 659                 17,568              **26.67**                
  Cm-PiFP-80           *Chelonia mydas* (green)               Principe Island, Western Africa              20.01                           16.79                 12,915              148,669             **11.51**                
  Cm-PiFP-82           *Chelonia mydas* (green)               Principe Island, Western Africa              24.10                           24.96                 937                 5,398               **5.76**                 
  Cm-TCFP-14           *Chelonia mydas* (green)               Turks & Caicos Islands, Caribbean Sea        20.80                           18.88                 8,244               56,811              **6.89**                 
  Cm-TCFP-2            *Chelonia mydas* (green)               Turks & Caicos Islands, Caribbean Sea        22.63                           20.62                 2,753               87,306              **31.71**                
  Cm-TCFP-3            *Chelonia mydas* (green)               Turks & Caicos Islands, Caribbean Sea        22.57                           21.80                 1,144               40,962              **35.82**                
  Cm-TCFP-5            *Chelonia mydas* (green)               Turks & Caicos Islands, Caribbean Sea        21.18                           21.15                 2,789               62,148              **22.28**                
  Cm-TCFP-8            *Chelonia mydas* (green)               Turks & Caicos Islands, Caribbean Sea        27.75                           26.14                 21                  4                   **0.19**                 
  FP non-tumoured      Cm-HaT-8                               *Chelonia mydas* (green)                     Hawaii, USA, Northern Pacific   21.73                 24.01               10,300              72                       **0.01**
  Cm-HaT-11            *Chelonia mydas* (green)               Hawaii, USA, Northern Pacific                20.04                           26.80                 3,900               416                 **0.11**                 
  Cm-HaT-14            *Chelonia mydas* (green)               Hawaii, USA, Northern Pacific                20.36                           28.96                 10,319              61                  **0.01**                 
  Cm-HaT-2             *Chelonia mydas* (green)               Hawaii, USA, Northern Pacific                25.16                           31.39                 1,093               0                   **0.00**                 
  Cm-HaT-3             *Chelonia mydas* (green)               Hawaii, USA, Northern Pacific                23.83                           30.82                 1,115               18                  **0.02**                 
  Cm-HaT-4             *Chelonia mydas* (green)               Hawaii, USA, Northern Pacific                26.54                           31.13                 196                 15                  **0.08**                 
  Cm-PiT-04            *Chelonia mydas* (green)               Principe Island, Western Africa              21.71                           27.63                 4,341               142                 **0.03**                 
  Cm-PiT-20            *Chelonia mydas* (green)               Principe Island, Western Africa              21.04                           27.26                 15,357              0                   **0.00**                 
  Cm-PiT-51            *Chelonia mydas* (green)               Principe Island, Western Africa              21.53                           29.20                 11,216              0                   **0.00**                 
  Cm-PiT-80            *Chelonia mydas* (green)               Principe Island, Western Africa              20.64                           26.75                 7,910               0                   **0.00**                 
  Cm-PiT-82            *Chelonia mydas* (green)               Principe Island, Western Africa              20.03                           29.54                 12,751              42                  **0.00**                 
  Clinically healthy   Cc-CyT-275                             *Caretta caretta* (loggerhead)               Northen Cyprus, Mediterranean   23.51                 23.18               1,566               16,905                   **10.80**
  Cc-CyT-346           *Caretta caretta* (loggerhead)         Northen Cyprus, Mediterranean                23.06                           26.84                 2,090               116                 **0.06**                 
  Cc-DkT-01            *Caretta caretta* (loggerhead)         Denmark, Danmarks Aquarium (not naturally)   23.32                           23.43                 1,769               14,401              **8.14**                 
  Cm-DkT-01liver       *Chelonia mydas* (green)               Denmark, Danmarks Aquarium (not naturally)   17.18                           29.83                 182,563             0                   **0.00**                 
  Cm-DkT-01mouth       *Chelonia mydas* (green)               Denmark, Danmarks Aquarium (not naturally)   18.53                           29.41                 33,367              45                  **0.00**                 
  Cm-DkT-01neck        *Chelonia mydas* (green)               Denmark, Danmarks Aquarium (not naturally)   20.34                           26.93                 11,959              66                  **0.01**                 
  Cm-DkT-01rearLF      *Chelonia mydas* (green)               Denmark, Danmarks Aquarium (not naturally)   22.48                           26.25                 3,031               379                 **0.13**                 
  Cm-ToT-37            *Chelonia mydas* (green)               Costa Rica, Tortuguero, Caribbean coast      24.85                           25.08                 663                 4,998               **7.54**                 
  Dc-GhT-22            *Dermochelys coriacea* (leatherback)   Ghana, Western Africa                        21.89                           28.02                 4,426               95                  **0.02**                 
  Dc-GhT-23            *Dermochelys coriacea* (leatherback)   Ghana, Western Africa                        22.63                           21.95                 2,753               37,205              **13.51**                
  Ei-KuT-kw5           *Eretmochelys imbricata* (hawksbill)   Qaru Island, Kuwait, Persian Gulf            20.10                           27.12                 13,949              192                 **0.01**                 
  Ei-KuT-kw7           *Eretmochelys imbricata* (hawksbill)   Qaru Island, Kuwait, Persian Gulf            21.29                           26.30                 6,503               230                 **0.04**                 
  Ei-PiT-25            *Eretmochelys imbricata* (hawksbill)   Principe Island, Western Africa              23.84                           23.02                 1,267               18,732              **14.78**                
  Ei-PiT-46            *Eretmochelys imbricata* (hawksbill)   Principe Island, Western Africa              23.68                           22.89                 1,404               20,361              **14.50**                
  Ei-PiT-71            *Eretmochelys imbricata* (hawksbill)   Principe Island, Western Africa              22.49                           22.11                 3,012               33,577              **11.15**                
  Ei-PiT-85            *Eretmochelys imbricata* (hawksbill)   Principe Island, Western Africa              24.21                           23.29                 1,000               15,754              **15.76**                

Results
=======

Consistent with previous observations ([@ref-24]; [@ref-30]), we observed that the highest viral loads (average ratio of 15.61, *s* ± 12.5) were in FP tumour samples, while the ratio of viral to nuclear DNA in FP non-tumour samples from FP infected animals were low to undetectable (average ratio of 0.02, *s* ± 0.00). However, tissue samples from clinically healthy animals were found to contain significantly higher viral loads of g*B* (average ratio of 6.03, W-t, *p* = 0.008, t-t, *p* = 0.002) than non-tumour samples from FP exhibiting turtles ([Fig. 1](#fig-1){ref-type="fig"}).

![Boxplot showing viral *g* B\[i\] load ratios by main three different health status categories.\
Proportional ratio between Glycoprotein *B* (*gB*) to endogenous nuclear (nuDNA) for the main three different health status categories of sea turtle tissue samples analysed. This ratio standardises values into a range from ≤1 indicating higher nuDNA than viral *gB*; to any value ≥1 which indicates higher viral *gB* loads than endogenous nuDNA.](peerj-04-2274-g001){#fig-1}

Although the starting tissue mass was only estimated to be similar between all samples, the estimated nuDNA levels were overall consistent ([Fig. 2A](#fig-2){ref-type="fig"}). Based on standard curve, we estimate that the median of g*B* is approximately 4.9^*E*+04^ copies/µL DNA extract in FP tumours, 1.8^*E*+01^ copies/µL in non-tumour tissue from FP animals and 5.8^*E*+04^ copies/µL in clinically healthy turtles ([Fig. 2B](#fig-2){ref-type="fig"}).

![Boxplot showing g B\[i\] and nuDNA copy numbers by main three different health status categories.\
(A) Estimated copy number of endogenous nuclear DNA for the main three different health status categories of sea turtle tissue samples analysed; (B) Estimated copy number of viral Glycoprotein B\[i\] according to the main three different health status categories of sea turtle tissue samples analysed.](peerj-04-2274-g002){#fig-2}

Discussion
==========

ChHV5 has been associated as primary etiological agent of FP by three lines of evidence. First, every tumour analysed by polymerase chain reaction (PCR) has yielded ChHV5 sequences ([@ref-13]; [@ref-2]), second, tumours occasionally show epidermal viral inclusions with ultrastructural similar to herpesvirus-like particles ([@ref-18]); and third, experimental transmission of the disease using cell-free tumour extracts inoculated into healthy turtles resulted in the development of FP disease ([@ref-14]). Nevertheless, the role of ChHV5 as causal agent for FP remains inconclusive as; (i) *in vitro* culturing has been repetitively unsuccessful and (ii) ChHV5 DNA can be also found in asymptomatic turtles ([@ref-2]).

The observation of higher levels of ChHV5 DNA in tumour versus non-tumour samples from FP exhibiting turtles was expected, as ChHV5 DNA burdens are increased within tumour tissues (see [Table 2](#table-2){ref-type="table"} and [Data S1](#supp-1){ref-type="supplementary-material"} ---copy number loads of g*B* and nuDNA per turtle sample grouped by health status tissue). What is remarkable though, is that on average, clinically healthy turtle samples exhibited viral to host DNA ratios that were significantly higher than those within non-tumour affected tissues of FP exhibiting turtles ([Fig. 2B](#fig-2){ref-type="fig"}). A key fact in this regard is that no visually observable FPs were reported for any of the 'healthy' turtles sampled during the tissue collection. Although ChHV5 DNA has previously been detected in skin samples from clinically healthy green, loggerhead and olive ridley turtles ([@ref-16]), these animals were from populations historically well documented containing FP infected turtles.

We reiterate that the small number of samples analysed in this study represent a sub-sample set from a larger number of turtle populations recently published work ([@ref-2]). Thus, all samples analysed here have been already detected viral DNA positive by PCR providing further evidence of actual presence of the herpesvirus. Our results however provide first evidence of viral loads in multiple sub-samples of clinically affected and healthy turtles from distant ocean basins across four species. In fact, the ratios of g*B* to turtle nuDNA were actually very high (\>10) in six of the clinically healthy turtles ([Fig. 1](#fig-1){ref-type="fig"}). These samples correspond to four hawksbill turtles from Principe Island, Western Africa, which are known to share feeding grounds with green turtle FP exhibiting populations ([@ref-7]); one leatherback from Ghana and one loggerhead in the Mediterranean ([Table 2](#table-2){ref-type="table"}). FP has rarely been documented in hawksbill ([@ref-12]; [@ref-5]) and leatherback ([@ref-17]) species, so the detection of ChHV5 g*B* DNA in these two species represent a quandary. Nuclear DNA levels were consistent among samples and routine use of negative and positive controls performed as expected, therefore, it is not suspected that these results are artefact of procedure. Furthermore, as with most alphaherpesviruses ChHV5 primarily appears to target skin tissue ([@ref-19]). Thus, the presence of ChHV5 g*B* DNA in skin from clinically healthy animals may represent an early stage of infection which remains in latency, and detection of viral concentrations in tumour-free animals may be a means of identifying animals that will eventually develop FP tumours ([@ref-24]) subjected to the appropriate co-factors triggering the infection. The mechanism underlying this phenomenon remains unclear and was not addressed in this study. There is no evidence that immunosuppression is needed for FP development, but there is evidence that FP does lead to immunosuppression in Hawaiian green turtles ([@ref-31]).

The g*B* gene selected for this study is an envelope protein that is only found in large amounts in intact virions undergoing lytic replication ([@ref-32]). As in FP in turtles, skin tumours are the only tissues where lytic replication with intact virions has been consistently documented ([@ref-30]), one would expect g*B* levels to be relatively high in these tissues. Thus, we were anticipating and expecting high levels of ChHV5 g*B* DNA in FP tumours, followed by relatively low in FP non-tumours and extremely low to absent in healthy tissue samples. However, high levels of herpesviral DNA in skin from clinically healthy animals suggest another not described process in regards to development of ChHV5 latency.

Many herpesviruses are maintained in sensory neurons in a latent state in which no clinical disease is produced and characterised by the repression of most viral lytic cycle genes and the abundant expression of certain types of viral RNA ([@ref-20]). Such repression of viral protein synthesis during latency has led to the general view of latency as being a quiescent and antigenically silent infection that is ignored by host immunity ([@ref-25]). However, very low levels of gene transcripts and proteins from all kinetic classes of herpes simplex virus have been detected in latently laboratory infected rodents ([@ref-9]). Previous studies have detected nucleosomes on the herpes simplex virus (HSV) genome during a lytic infection ([@ref-6]) that are not arranged in an equally spaced array like in cellular DNA. However, as in cellular DNA, the promoter regions of several viral genes have been shown to be associated with nucleosomes containing modified histone proteins that are generally found associated with actively transcribed genes ([@ref-23]). Because no histones were detected inside HSV type 1 capsids, the viral genome probably starts to associate with histones after being transported from infecting virions into the host nucleus. This represents evidence that a herpesvirus genome can remain intact in the host nucleus disassociated from the viral envelope protection. Thus, we propose that a similar situation exists in turtles latently infected with ChHV5, where our data provides evidence of g*B* DNA being consistently present in clinically healthy marine turtles across four different species. We caution here that our methods detect only a portion of the g*B* DNA and does not imply production of lytic virus in normal skin from FP free animals.

While Koch's postulates are still regarded as the most compelling proof of causation, there are documented instances where disease agents cannot be cultured, yet are now known to be causative ([@ref-21]), such as the herpes simplex and polio viruses. Although a 21st century adaptation of Koch's postulates ([@ref-10]) have been proposed to reflect the introduction of culture-independent molecular methods, these updated criteria are also not yet fulfilled by ChHV5. Thus, ChHV5's association with FP remains tantalising, yet unsolved.

In summary, our findings offer evidence that clinically healthy marine turtles from distant sites worldwide where FP has not been reported yet across species carry ChHV5 DNA through persistent latent infections, often at very high levels. This in turn provides additional evidence for hypotheses ([@ref-15]; [@ref-27]) that ChHV5 is a near ubiquitous virus and alone does not cause infection, but requires one or more possibly environmental or immune related co-factors or triggers to induce FP.

Supplemental Information
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###### Copy number loads of g B\[i\] and nuDNA per turtle sample grouped by health status tissue

Copy number loads of viral Glycoprotein B *(g B*) and endogenous turtle-host nuclear (nuDNA) per each individual sample grouped by health status type of tissue-values presented in log~10~ scale.

###### 

Click here for additional data file.
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Click here for additional data file.
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Approvals for the work in Turks and Caicos Islands were obtained through the Department of Environment and Maritime Affairs (DEMA). Nesting beaches (some within protected areas) were accessed with permission from landowners and DEMA. All harvested turtles were sampled as part of the legal turtle fishery with permission from fishermen, processing plants and DEMA. Samples were exported using multiple CITES permits and UK Animal Health and Veterinary Laboratories Agency permits. Permits and sample collection from Principe Island were carried out in cooperation between Zoomarine and the Faculty of Science and Technology at University of Algarve, Portugal.

Most healthy tissue samples were collected from necrotic stranded turtles. Samples from Kuwait and Costa Rica were originated from live animals following protocols approved by Kuwaiti Coast Guard and Universidad de Costa Rica (UCR) in cooperation with the Costa Rican Ministry of Environment and Energy (MINAE), respectively. Tissue sample collection followed different protocols from our various collaborators, however the majority were obtained from either skin of front flipper or neck of the turtles.

The following information was supplied regarding data availability:

The raw data has been supplied as [Data S1](#supp-1){ref-type="supplementary-material"}.
